Statins for osteoporosis in postmenopausal women
Referencias
Additional references
Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewicz‐Sapuntzakis M, Guo P, et al. Dietary soybean protein prevents bone loss in an ovarectomized rat model of osteoporosis. Journal of Nutrition 1996;126(1):161‐7.
Barnes S. What is a safe level of phytoestrogen intake?. Annals of Nutrition and Metabolism 2001;45:219.
Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture. Results of 4 prospective studies and cumulative meta‐analysis of observational studies and controlled trials. Annal of Internal Medicine 2004;164(2):146‐52.
Cates C. EBM website. http://www.nntonline.net/2003 (accessed 26 June, 2007).
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis International 2000;11(7):556‐61.
Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. Journal of Clinical Endocrinology and Metabolism 2001;86(9):4556‐9.
Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta‐analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta‐analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002;23(4):570‐8.
Edwards CJ, Russell RG, Spector TD. Statins and bone: myth or reality?. Calcified Tissue International 2001;69(2):63‐6.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.
Gambacciani M, Ciaponi M. Postmenopausal osteoporosis management. Current Opinion in Obstetrics & Gynecology 2000;12(3):189‐97.
Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. A harmacological review of selective oestrogen receptor modulators. Human Reproduction Update 2000;6(3):212‐24.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporosis International 2004;15(11):897‐902.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone 2003;32(5):468‐73.
Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis International 2004;16(3):229‐38.
LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Annal of Internal Medicine 2003;139(2):I27.
Leslie WD, Adler RA, El‐Hajj Fuleihan G, Hodsman AB, Kendler DL, McClung M, et al. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. Journal of Clinical Densitometry 2006;9(1):22‐30.
Li M, Jiao J, Meng XW, Xing XP, Xia WB, Zhou XY, et al. Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats. Chinese Medical Journal 2005 Feb 2;85(5):335‐8.
Lindsay R. The oestrogen receptor in bone ‐ evolution of our knowledge. British Journal of Obstetrics and Gynaecology 1996;103 suppl. 13:16‐8; discussion 18‐9.
Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3‐E1 cells. Biochemical and Biophysical Research Communications 2001;280(3):874‐7.
Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG‐CoA reductase inhibitors and the risk of fractures. JAMA 2000;283(24):3205‐10.
Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1‐year longitudinal study. Bone 2003;32(4):427‐33.
Mundy GR. Osteoporosis into the year 2010. British Journal of Obstetrics and Gynaecology 1996;103(suppl. 13):32‐8.
Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286(5446):1946‐9.
Mundy GR. Statins and their potential for osteoporosis. Bone 2001;29(6):495‐7.
National Guideline Clearinghouse. Diagnosis of osteoporosis in men, premenopausal women, and children. Journal of Clinical Densitometry 2004;7(1):17‐26.
NIH consensus development panel on osteoporosis prevention and diagnosis. Osteoporosis prevention, diagnosis, prophylaxis and treatment. JAMA2001; Vol. 285, issue 6:785‐95.
Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporosis fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research 1997 Jan;12(1):24‐35.
Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. Journal of Bone and Mineral Research 2005;20(2):177‐84.
Riis BJ. Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis. American Journal of Medicine 1993 Nov 30;95(5A):17S‐21S.
Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359(9320):1841‐50.
Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, et al. Relation of statin use and bone loss: a prospective population‐based cohort study in early postmenopausal women. Osteoporosis International 2002;13(7):537‐41.
Somekawa Y, Wakabayashi A. Relationship between apolipoprotein E polymorphism, menopausal symptoms and serum lipids during hormone replacement therapy. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1998;79(2):185‐91.
Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein‐2 in human osteosarcoma cells. Biochemical and biophysical research communications 2000;271(3):688‐92.
Thompson RB. Foundations for blockbuster drugs in federally sponsored research. Journal of the Federation of American Societies for Experimental Biology 2001;15(10):1671‐6.
Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (editors). Evidence‐based Rheumatology. London: BMJ Books, 2004.
U.S. Department of Health and Human Service. Bone health and osteoporosis: a report of the surgeon general (2004). http://www.surgeongeneral.gov/library/bonehealth/. Rockville, MD, USA: Office of the Surgeon General, (accessed 25 June 2007):1‐436.
Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta‐analysis of clinical studies. Bone 2007;40(6):1581‐7.
Van Harrison, Robert Lash, Jane McCort, Yolanda Smith, Lourdes Velez. Osteoporosis: prevention and treatment. http://www.guideline.gov/summary/summary.aspx?doc_id=7983&nbr=4492 Updated in 2005 (accessed 25 June 2007).
Wang PS, Solomon DH, Mogun H, Avorn J. HMG‐CoA reductase inhibitors and the risk on hip fractures. JAMA 2000;283(24):3211‐6.
Taixiang Wu, Guanjian Liu. What about the concepts, design, practice and report of allocation concealment and blinding exactly?. Chinese Journal of Evidence‐Based Medicine 2007;7(3):203‐7.
Zhou ZW, Li X. The diagnosis and treatment of primary osteoporosis. The Journal of Chinese Geriatrics 2003;22(6):328.
